Biocardia Inc (BCDA)

$1.98 +0.00 (0.15%)
Market Cap 11.47M
Revenue (ttm) 60,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,250.00%
Debt to Equity Ratio 0.00
Volume 24,500
Avg Vol 367,226
Day's Range N/A - N/A
Shares Out 5.80M
Stochastic %K 89%
Beta 0.85
Analysts Strong Sell
Price Target $15.50

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 226 0120
Fax: 650 631 3731
Address:
320 Soquel Way, Sunnyvale, United States
wereese
wereese Sep. 1 at 11:28 PM
$BCDA when we expecting news here?
0 · Reply
BioTerror
BioTerror Aug. 27 at 4:56 PM
$BCDA primed ready to go 🚀
1 · Reply
TheUnmaker
TheUnmaker Aug. 27 at 3:46 PM
$GRAL These market makers may be friendly, but they're not your friends. $HCWB $BCDA
0 · Reply
BioTerror
BioTerror Aug. 26 at 9:16 PM
$TTNP and she's gone. Will fly in PM tomorrow. Only 900k float. 😤 $CPHI $BCDA $THAR
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 9:04 PM
$BCDA Waiting for the market maker shakeout on this bad mama jammer.. then we loaaaad up! Always early to get in before the musical chairs event! $HCWB
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 5:47 PM
$HCWB All you longs here need to take a look at $BCDA.. this the next big bio runner!
0 · Reply
peepthestamp
peepthestamp Aug. 25 at 4:21 PM
👀 $PSTV: Earnings turnaround + insider buy = conviction-backed setup. $LUCD: Strong cash and reimbursement pathway support stability. $IRIX: Funding and profitability lining up — healthy steady performer in med-tech. $BCDA: Advancing clinical & regulatory pipeline in regenerative med — asymmetric upside.
1 · Reply
BioTerror
BioTerror Aug. 25 at 3:53 PM
$THAR called it at 1.26 when no one wanted it. Now $BCDA will make similar run. Load up under $2! 😤
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 25 at 3:40 PM
$BCDA CEO purchased 700 shares at $1.83 for a total of $1,281. Altman Peter now owns 168,762 shares. https://ceo-buys.com
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 25 at 3:35 PM
$BCDA CEO purchased 700 shares at $1.83 for a total of $1,281. Altman Peter now owns 168,762 shares. https://ceo-buys.com
0 · Reply
Latest News on BCDA
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 8:37 PM EDT - 22 days ago

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 11, 2025, 9:15 AM EDT - 22 days ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 6, 2025, 3:18 PM EDT - 27 days ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

Aug 4, 2025, 6:00 AM EDT - 4 weeks ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 21, 2025, 8:30 AM EDT - 3 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:40 PM EDT - 3 months ago

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 14, 2025, 4:05 PM EDT - 3 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

May 9, 2025, 4:28 PM EDT - 4 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Apr 11, 2025, 9:15 AM EDT - 5 months ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 11:30 PM EDT - 5 months ago

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 31, 2025, 1:39 PM EDT - 5 months ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 26, 2025, 4:30 PM EDT - 5 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 21, 2025, 8:30 AM EDT - 5 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Mar 10, 2025, 9:15 AM EDT - 6 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 27, 2025, 9:15 AM EST - 6 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Feb 13, 2025, 8:30 AM EST - 7 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Jan 27, 2025, 9:15 AM EST - 7 months ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Dec 4, 2024, 8:30 AM EST - 9 months ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:49 PM EST - 10 months ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:53 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Jun 7, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

BioCardia Announces Reverse Stock Split

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 14, 2024, 4:02 PM EDT - 1 year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 9, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

May 1, 2024, 7:00 AM EDT - 1 year ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Apr 25, 2024, 9:00 AM EDT - 1 year ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 27, 2024, 4:00 PM EDT - 1 year ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 13, 2024, 7:00 AM EDT - 1 year ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 12, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Mar 4, 2024, 8:00 AM EST - 1 year ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Feb 8, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 31, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Dec 18, 2023, 7:16 AM EST - 1 year ago

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Nov 29, 2023, 7:00 AM EST - 1 year ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Nov 16, 2023, 12:56 PM EST - 1 year ago

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Nov 14, 2023, 7:15 AM EST - 1 year ago

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 8:08 PM EST - 1 year ago

BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 8, 2023, 4:11 PM EST - 1 year ago

BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

Nov 1, 2023, 5:04 PM EDT - 1 year ago

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

wereese
wereese Sep. 1 at 11:28 PM
$BCDA when we expecting news here?
0 · Reply
BioTerror
BioTerror Aug. 27 at 4:56 PM
$BCDA primed ready to go 🚀
1 · Reply
TheUnmaker
TheUnmaker Aug. 27 at 3:46 PM
$GRAL These market makers may be friendly, but they're not your friends. $HCWB $BCDA
0 · Reply
BioTerror
BioTerror Aug. 26 at 9:16 PM
$TTNP and she's gone. Will fly in PM tomorrow. Only 900k float. 😤 $CPHI $BCDA $THAR
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 9:04 PM
$BCDA Waiting for the market maker shakeout on this bad mama jammer.. then we loaaaad up! Always early to get in before the musical chairs event! $HCWB
0 · Reply
TheUnmaker
TheUnmaker Aug. 25 at 5:47 PM
$HCWB All you longs here need to take a look at $BCDA.. this the next big bio runner!
0 · Reply
peepthestamp
peepthestamp Aug. 25 at 4:21 PM
👀 $PSTV: Earnings turnaround + insider buy = conviction-backed setup. $LUCD: Strong cash and reimbursement pathway support stability. $IRIX: Funding and profitability lining up — healthy steady performer in med-tech. $BCDA: Advancing clinical & regulatory pipeline in regenerative med — asymmetric upside.
1 · Reply
BioTerror
BioTerror Aug. 25 at 3:53 PM
$THAR called it at 1.26 when no one wanted it. Now $BCDA will make similar run. Load up under $2! 😤
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 25 at 3:40 PM
$BCDA CEO purchased 700 shares at $1.83 for a total of $1,281. Altman Peter now owns 168,762 shares. https://ceo-buys.com
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 25 at 3:35 PM
$BCDA CEO purchased 700 shares at $1.83 for a total of $1,281. Altman Peter now owns 168,762 shares. https://ceo-buys.com
0 · Reply
BioTerror
BioTerror Aug. 25 at 3:16 PM
$THAR low float bio stocks are hot... $BCDA is next after $HCWB 😤🚀🚀
0 · Reply
TheUnmaker
TheUnmaker Aug. 23 at 3:16 PM
$BCDA Big things coming.. talked to some people over at Biocardia. I got the green light. I'm in again.
1 · Reply
SpaceXStonks
SpaceXStonks Aug. 23 at 7:06 AM
$BCDA BioCardia Inc is a clinical stage cell therapy company with funding challenges
0 · Reply
BOUDIN420
BOUDIN420 Aug. 23 at 5:55 AM
$BCDA
0 · Reply
BOUDIN420
BOUDIN420 Aug. 23 at 5:51 AM
$BCDA
0 · Reply
BOUDIN420
BOUDIN420 Aug. 23 at 1:21 AM
$BCDA DD = sleeper...
1 · Reply
BioTerror
BioTerror Aug. 22 at 8:03 PM
$BCDA news dropping any day now... expecting big spike over $3 soon!
1 · Reply
BioTerror
BioTerror Aug. 20 at 5:12 PM
$BCDA called Thar early.. this one is next 🚀
1 · Reply
kolococo
kolococo Aug. 20 at 4:01 AM
$BCDA buying
1 · Reply
TheUnmaker
TheUnmaker Aug. 18 at 10:45 PM
$GRAL I always wait for that sub $32 dip and I buy more everyday. $HCWB $HSCS $BCDA
1 · Reply
TheUnmaker
TheUnmaker Aug. 16 at 1:02 PM
$BCDA Has their manufacturing been audited?
0 · Reply
TheUnmaker
TheUnmaker Aug. 15 at 4:08 PM
$HCWB Nice day for cheapies here.. added $BCDA $HSCS $GRAL $UNH
0 · Reply